GlaxoSmithKline expands England R&D facility, plans on raising $552.76M

On Friday, British pharma giant GlaxoSmithKline said, it plans to set up a new life sciences campus within its R&D site in Stevenage, England, by raising up to $552.76 million (400 million pounds) by selling some land at the facility.

In a statement London-listed GlaxoSmithKline said, it expects to select a private-sector developer later this year and sell 33 acres from its 92-acre site. Work on the UK government-backed project is expected to begin next year.

Locking horns with activist investor Elliot Management, GSK is preparing for a planned spin-off of its consumer healthcare venture and focus on its prescription drugs and vaccines business, to develop a new line of products. 

“Our goal is for Stevenage to emerge as the top destination for medical and scientific research by the end of the decade,” said Tony Wood, a senior executive at GSK.

The company aims to create up to 5,000 jobs in the next five to 10 years following the addition of the new campus.

($1 = 0.7236 pounds)

Categories: Creativity, Economy & Finance, Entrepreneurship, HR & Organization, Strategy

Tags: , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: